Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Sabino Arana 5-19, 08028, Barcelona, Spain.
Instituto Oncológico Dr Rosell (IOR), University Hospital Sagrat Cor, QuironSalud Group, Viladomat 288, 08029, Barcelona, Spain.
Curr Oncol Rep. 2018 Jul 20;20(9):70. doi: 10.1007/s11912-018-0720-z.
Liquid biopsies have potential as tools for diagnosis, prognosis, and prediction of response to therapy. Herein, we will extensively review four liquid biosources, tumor-educated platelets (TEPs), cell-free DNA (cfDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) and we will clarify their optimal application in non-small cell lung cancer (NSCLC) diagnosis and therapy.
Liquid biopsies are a minimally invasive alternative to tissue biopsies-especially important in NSCLC patients-since tumor tissue is often unavailable or insufficient for complete genetic analysis. The main advantages of liquid biopsies include the possibility for repeated sampling, the lower cost, and the fact that they can reflect the complete molecular status of the patient better than a single-site biopsy. This is specifically important for lung adenocarcinoma patients since the detection of specific genetic alterations can predict response to targeted therapies. Molecular analysis is currently cardinal for therapy decision-making and disease monitoring in lung cancer patients. Liquid biopsies can make easier our daily clinical practice and if prospectively tested and validated may serve as a means for lung cancer early detection.
液体活检作为一种用于诊断、预后和预测治疗反应的工具具有一定的潜力。在此，我们将广泛综述四种液体生物源，即肿瘤诱导的血小板（TEPs）、游离 DNA（cfDNA）、循环肿瘤细胞（CTCs）和细胞外囊泡（EVs），并阐明它们在非小细胞肺癌（NSCLC）诊断和治疗中的最佳应用。
液体活检是组织活检的一种微创替代方法，对于 NSCLC 患者尤其重要，因为肿瘤组织通常无法获得或不足以进行完整的基因分析。液体活检的主要优势包括重复采样的可能性、成本更低以及能够比单次活检更好地反映患者的完整分子状态，这对于肺腺癌患者尤其重要，因为检测到特定的遗传改变可以预测对靶向治疗的反应。分子分析目前是肺癌患者治疗决策和疾病监测的关键。液体活检可以使我们的日常临床实践更加容易，如果经过前瞻性测试和验证，可能成为肺癌早期检测的一种手段。
